• 1
    Adinoff AD, Hollister JR. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 1983; 309: 2658.
  • 2
    Dykman TR, Gluck OS, Murphy WA, Hahn TJ, Hahn BH. Evaluation of factors associated with glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum 1985; 28: 3618.
  • 3
    Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990; 112: 35264.
  • 4
    Reid IR, Grey AB. Corticosteroid osteoporosis. Baillieres Clin Rheumatol 1993; 7: 57387.
  • 5
    LoCascio V, Bonucci E, Imbimbo B, Ballanti P, Adami S, Milani S, et al. Bone loss in response to long-term glucocorticoid therapy. Bone 1990; 8: 3951.
  • 6
    Canalis E. Clinical review 83. Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. J Clin Endocrinol Metab 1996; 81: 34417.
  • 7
    Reid IR. Pathogenesis and treatment of steroid osteoporosis. Clin Endocrinol 1989; 30: 83103.
  • 8
    Hahn TJ. Corticosteroid-induced osteopenia. Arch Intern Med 1978; 138: 8825.
  • 9
    Lund B, Andersen RB, Friis T, Hjorth L, Jorgensen FS, Norman AW, et al. Effect of 1alpha-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 on intestine and bone in glucocorticoid-treated patients. Clin Endocrinol 1977; 7 Suppl: 177s81s.
  • 10
    Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson PD, Selznick SH, et al. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 1998; 13: 32549.
  • 11
    Braun JJ, Birkenhager-Frenkel DH, Rietveld AH, Juttmann JR, Visser TJ, Birkenhager JC. Influence of 1 alpha-(OH)D3 administration on bone and bone mineral metabolism in patients on chronic glucocorticoid treatment; a double blind controlled study. Clin Endocrinol 1983; 19: 26573.
  • 12
    Hahn TJ, Halstead LR, Teitelbaum SL, Hahn BH. Altered mineral metabolism in glucocorticoid-induced osteopenia: effect of 25-hydroxyvitamin D administration. J Clin Invest 1979; 64: 65565.
  • 13
    Rao LG, Wylie JN, Kung Sutherland MS, Murray TM. 17 beta-oestradiol enhances the stimulatory effect of 1,25-dihydroxyvitamin D3 on alkaline phosphatase activity in human osteosarcoma SaOS-2 cells in a differentiation-dependent manner. J Endocrinol 1996; 148: 1817.
  • 14
    Bikle DD. Role of vitamin D, its metabolites, and analogs in the management of osteoporosis. Rheum Dis Clin North Am 1994; 20: 75975.
  • 15
    Price PA, Baukol SA. 1,25-dihydroxyvitamin D3 increases synthesis of the vitamin K-dependent bone protein by osteosarcoma cells. J Biol Chem 1980; 255: 116603.
  • 16
    Roodman GD, Ibbotson KJ, MacDonald BR, Kuehl TJ, Mundy GR. 1,25-dihydroxyvitamin D3 causes formation of multinucleated cells with several osteoclast characteristics in cultures of primate marrow. Proc Natl Acad Sci U S A 1985; 82: 82137.
  • 17
    Bar-Shavit Z, Teitelbaum SL, Reitsma P, Hall A, Pegg LE, Trial J, et al. Induction of monocytic differentiation and bone resorption by 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci U S A 1983; 80: 590711.
  • 18
    Hahn TJ, Hahn BH. Osteopenia in patients with rheumatic diseases: principles of diagnosis and therapy. Semin Arthritis Rheum 1976; 6: 16588.
  • 19
    Sorensen OH, Lund B, Friis TH, Hjorth L, Reimann I, Kjaer I, et al. Effect of 1alpha-hydroxycholecalciferol in senile osteoporosis and in bone loss following prednisone treatment. Isr J Med Sci 1977; 13: 2538.
  • 20
    Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996; 125: 9618.
  • 21
    Dykman TR, Haralson KM, Gluck OS, Murphy WA, Teitelbaum SL, Hahn TJ, et al. Effect of oral 1,25-dihydroxyvitamin D and calcium on glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum 1984; 27: 133643.
  • 22
    Bijlsma JW, Raymakers JA, Mosch C, Hoekstra A, Derksen RH, Baart de la Faille H, et al. Effect of oral calcium and vitamin D on glucocorticoid-induced osteopenia. Clin Exp Rheumatol 1988; 6: 1139.
  • 23
    Garcia-Delgado I, Prieto S, Gil-Fraguas L, Robles E, Rufilanchas JJ, Hawkins F. Calcitonin, etidronate, and calcidiol treatment in bone loss after cardiac transplantation. Calcif Tissue Int 1997; 60: 1559.
  • 24
    Healey JH, Paget SA, Williams-Russo P, Szatrowski TP, Schneider R, Spiera H, et al. A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica. Calcif Tissue Int 1996; 58: 7380.
  • 25
    Bijlsma JW. Prevention of glucocorticoid induced osteoporosis. Ann Rheum Dis 1997; 56: 5079.
  • 26
    American College of Rheumatology Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 1996; 39: 1791801.
  • 27
    Sambrook PN. Which treatments are effective in preventing and treating glucocorticoid-induced bone loss: comment on the American College of Rheumatology recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis [letter]. Arthritis Rheum 1997; 40: 15501.
  • 28
    Ringe JD. Active vitamin D metabolites in glucocorticoid-induced osteoporosis. Calcif Tissue Int 1997; 60: 1247.
  • 29
    Eastell R. Management of corticosteroid-induced osteoporosis: UK Consensus Group Meeting on Osteoporosis. J Intern Med 1995; 237: 43947.
  • 30
    Hahn TJ, Boisseau VC, Avioli LV. Effect of chronic corticosteroid administration on diaphyseal and metaphyseal bone mass. J Clin Endocrinol Metab 1974; 39: 27482.
  • 31
    Glass GV. Primary, secondary and meta-analysis of research. Educ Researcher 1976; 5: 38.
  • 32
    Hedges LV. Distribution theory for Glass's estimator of effect size and related estimators. J Educ Stat 1981; 6: 10728.
  • 33
    Hedges LV, Olkin O. Statistical methods for meta-analysis. San Diego (CA): Academic Press; 1985.
  • 34
    Whitehead A, Whitehead J. A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med 1991; 10: 166577.
  • 35
    DuMouchel WH. Bayesian meta-analysis. New York: Marcel-Dekker; 1990.
  • 36
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials 1986; 7: 17788.
  • 37
    Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale (NJ): Lawrence Erlbaum Associates; 1988.
  • 38
    Greenland S. Invited commentary: a critical look at some popular meta-analytic methods. Am J Epidemiol 1994; 140: 2906.
  • 39
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 62934.
  • 40
    Di Munno O, Beghe F, Favini P, Di Giuseppe P, Pontrandolfo A, Occhipinti G, et al. Prevention of glucocorticoid-induced osteopenia: effect of oral 25-hydroxyvitamin D and calcium. Clin Rheumatol 1989; 8: 2027.
  • 41
    Bernstein CN, Seeger LL, Anton PA, Artinian L, Geffrey S, Goodman W, et al. A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. Aliment Pharmacol Ther 1996; 10: 77786.
  • 42
    Vogelsang H, Ferenci P, Resch H, Kiss A, Gangl A. Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation. Eur J Gastroenterol Hepatol 1995; 7: 60914.
  • 43
    Poubelle PE, Adachi J, Hawkins F, Goemaere S, Thamsborg G, Delmas P, et al. Alendronate increases bone mineral density in patients on glucocorticoid therapy: results of the multinational study [abstract]. Arthritis Rheum 1997; 40 Suppl 9: S327.
  • 44
    Saag K, Emkey R, Gruber B, Tesser J, Lane N, Yanover M, et al. Alendronate for the management of glucocorticoid-induced osteoporosis: results of the multicenter U.S. study [abstract]. Arthritis Rheum 1997; 40 Suppl 9: S136.
  • 45
    Pitt P, Li F, Mackintosh C, Todd P, Pack S, Webber D, et al. A double-blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term corticosteroids [abstract]. J Bone Miner Res 1997; 12 Suppl 1: S510.
  • 46
    Reginster JY, Kuntz D, Verdicht W, Wouters M, Guillevin L, Menkes C-J, et al. Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis [abstract]. Bone 1997; 20.
  • 47
    Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998; 339: 2929.
  • 48
    Adachi JD, Bensen WG, Bianchi F, Cividino A, Pillersdorf S, Sebaldt RJ, et al. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup. J Rheumatol 1996; 23: 9951000.
  • 49
    Christensen RS, Alex NH, Perloff JJ, Georgitis WJ, McDermott MT. Coherence therapy for steroid-induced osteoporosis, one-year report [abstract]. 77th Annual Meeting of the Endocrine Society; 1995 June 14–17; Washington, DC.
  • 50
    Diamond T, McGuigan L, Schonell M, Levy S, Rae D. A 2 year open randomized controlled trial comparing calcitriol to cyclic etidronate for the treatment of glucocorticoid-induced osteoporosis [abstract]. J Bone Miner Res 1997; 12 Suppl 1: S511.
  • 51
    Emkey R, Shen V, Lyssy J, Dempster DW, Lindsay R. A prospective, randomized study of vitamin D and calcium in the treatment of steroid induced osteoporosis in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 1994; 37 Suppl 9: S183.
  • 52
    Emkey R, Procaccini R, Gaich G. The effect of calcitonin on bone mass in steroid-induced osteoporosis [abstract]. Arthritis Rheum 1994; 37 Suppl 9: S183.
  • 53
    Henderson NK, Marshall G, Sambrook PN, Keogh A, Eisman JA. Prevention of bone loss after heart or lung transplantation [abstract]. J Bone Miner Res 1997; 12 Suppl: S400.
  • 54
    Lakatos P, Kiss L, Horvath C, Takacs I, Foldes J, Bossanyi A, et al. Glukokortikoidok okozla csontvestes merseklese alfacalcidollal (prevention of corticosteroid-induced osteoporosis with alphacalcidol). Lege Artis Medicinae 1996; 6: 6249.
  • 55
    Lems WF, Jacobs JWG, Bijlsma JWJ, Croone A, Houben HHML, Haanen HCM, et al. Corticosteroids and bone [thesis]. Utrecht (The Netherlands): Univ. of Utrecht; 1996.
  • 56
    Lippuner K, Haller B, Casez JP, Montandon A, Jaeger P. Effect of disodium monofluorophosphate, calcium and vitamin D supplementation on bone mineral density in patients chronically treated with glucocorticosteroids: a prospective, randomized, double-blind study. Miner Electrolyte Metab 1996; 22: 20713.
  • 57
    Pitt P, Li F, Todd P, Webber D, Pack S, Moniz C. A double-blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long term oral corticosteroid treatment. Thorax 1998; 53: 3516.
  • 58
    Reginster JY, Kuntz D, Verdicht W, Wouters M, Guillevin L, Menkes C-J, et al. Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Osteoporos Int 1999; 9: 7581.
  • 59
    Sambrook P, Birmingham J, Kelly P, Kempler S, Nguyen T, Pocock N, et al. Prevention of corticosteroid osteoporosis: a comparison of calcium, calcitriol, and calcitonin. N Engl J Med 1993; 328: 174752.
  • 60
    Sambrook PN, Marshall G, Henderson K, Keogh A, MacDonald P, Spratt P, et al. Effect of calcitriol in the prevention of bone loss after cardiac or lung transplantation [abstract]. J Bone Miner Res 1997; 12 Suppl 1: S400.
  • 61
    Schaadt OP, Bohr HH. Alfacalcidol in prednisone treatment—a controlled study of effect on bone mineral content in lumbar spine, femoral neck and shaft [abstract]. Calcif Tissue Int 1986; 39 Suppl: A58.
  • 62
    Talalaj M, Gradowska L, Marcinowska-Suchowierska E, Durlik M, Gaciong Z, Lao M. Efficiency of preventive treatment of glucocorticoid-induced osteoporosis with 25-hydroxyvitamin D3 and calcium in kidney transplant patients. Transplant Proc 1996; 28: 34857.
  • 63
    Warady BD, Lindsley CB, Robinson FG, Lukert BP. Effects of nutritional supplementation on bone mineral status of children with rheumatic diseases receiving corticosteroid therapy. J Rheumatol 1994; 21: 5305.
  • 64
    Schwartzman MS, Franck WA. Vitamin D toxicity complicating the treatment of senile, postmenopausal, and glucocorticoid-induced osteoporosis: four case reports and a critical commentary on the use of vitamin D in these disorders. Am J Med 1987; 82: 22430.
  • 65
    Jacobus CH, Holick MF, Shao Q, Chen TC, Holm IA, Kolodny JM, et al. Hypervitaminosis D associated with drinking milk. N Engl J Med 1992; 326: 11737.
  • 66
    Adams JS, Lee G. Gains in bone mineral density with resolution of vitamin D intoxication. Ann Intern Med 1997; 127: 2036.
  • 67
    Lukert BP, Kipp D, Broy S. Management of glucocorticoid-induced osteoporosis—first, do no harm: comment on the American College of Rheumatology recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis [letter]. Arthritis Rheum 1997; 40: 1548.